These Are the Only 3 Stocks That Cathie Wood Bought Last Week

Key Points
Cathie Wood added to her stakes in Figma, Arcturus Therapeutics, and 10x Genomics last week.
Analysts see Figma's growth slowing dramatically in the next two years, but an 83% drop from last year's high makes it a compelling consideration.
Arcturus revenue is going the wrong way, but strong liquidity and the potential of its leading candidate makes it a biotech that Wood bought three times last week.
- 10 stocks we like better than Figma ›
Last week was challenging for most investors. The three major market indexes moved lower for the fourth consecutive week. Growing investing icon Cathie Wood -- the founder, CEO, and primary stock picker of Ark Invest's family of ETFs -- has historically used pullbacks to load up on falling favorites, but she was surprisingly quiet this time.
Ark Invest added to only three existing positions last week. She bought shares in Figma (NYSE: FIG), Arcturus Therapeutics Holdings (NASDAQ: ARCT), and 10x Genomics (NASDAQ: TXG). Having a light hand as many of her stocks corrected is unusual for Wood, but it should also find investors hungry to understand why she chose these three names. Let's take a closer look at Wood's latest Ark Invest purchases.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
1. Figma
One of the hottest IPOs out of the gate last year has cooled down in a major way. Figma, a provider of website design for websites, apps, and other digital formats, has plummeted 83% from last summer's highs, a peak it achieved after more than quadrupling from its original $33 offering price.
Figma stock is one of the many cloud-based platforms getting slammed by a dramatic shift in market sentiment. The bearish narrative has providers of premium software-as-a-service (SaaS) stocks eventually coming under competitive pressure from cheaper, if not free, artificial intelligence (AI) solutions.
But Figma's popularity isn't waning. Revenue growth actually accelerated in its latest quarter. Year-over-year top-line growth hit 40% in the final three months of last year, up from a 38% increase in the previous quarter and well above the 35% rise it was initially projecting. The shares popped higher on last month's blowout quarter, only to give back those gains -- and then some.
Its net dollar-retention rate of 136% is stellar, indicating that returning customers over the past 12 months are spending 36% more on the platform than they were a year earlier. It's Figma's healthiest showing on that front in two years.
Figma is dealing with margin pressure. Its lack of reported healthy profitability has also prevented the creation of a floor for investors. Analysts see revenue growth slowing to 30% this year and 20% next year, but it's one of the more compelling broken IPOs of last year.
2. Arcturus Therapeutics
Ark didn't make any stock purchases on Monday or Tuesday of last week. Wood bought just one company on Wednesday, and this was it. She then added to her Arcturus Therapeutics stake in each of the final three trading days of the week.
Ark has plenty of biotechnology stocks on its scorecard, and Arcturus keeps a pretty low profile. Revenue has fallen sharply in each of the past three years. Its top line is expected to be cut in half again this year.
However, most emerging biotechs aren't about the past or even the near future. Arcturus uses messenger RNA tech to develop therapies for rare respiratory and liver diseases. Earlier this month, it announced its fourth-quarter results. The numbers weren't great, but it had positive news for some of its candidates going through clinical trials. It also revealed that it recently expanded its cash runway, giving it until at least the second quarter of 2028 before its bleeds through its current reserves.
3. 10x Genomics
Investors associate the term 10x with a company delivering a tenfold return. 10x Genomics is close, at least in terms of its long-term revenue growth. The provider of life sciences tools has seen its top line rise in seven of the past eight years, a ninefold increase over that period.
Unfortunately, shareholders haven't seen that kind of jump. 10x Genomics went public at $38 six summers ago. It's currently trading for half that price.
10x Genomics developed the Chromium platform, which has emerged as the top choice for businesses seeking single-cell genomic analysis. It offers solutions for whole-genome sequencing, single-cell transcriptomics, and exome sequencing. This is an important market in Wood's eyes. Ark owns several genetic sequencing stocks.
Two things are holding 10x Genomics back right now. The first is that it has never been profitable, and analysts don't see profitability happening on a reported basis anytime soon. The second pressure point is that its own guidance for this year calls for revenue to decline in 2026. 10x Genomics notes that its guidance implies a 0% to 4% increase, excluding nonrecurring licensing and loyalty revenue related to patent litigation settlements last year. It's a fair exclusion, but even then, it's not impressive growth.
Should you buy stock in Figma right now?
Before you buy stock in Figma, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Figma wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $495,179!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,058,743!*
Now, it’s worth noting Stock Advisor’s total average return is 898% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of March 23, 2026.
Rick Munarriz has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends 10x Genomics and Figma. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.